XML 28 R11.htm IDEA: XBRL DOCUMENT v3.22.1
Goodwill and Intangible Assets
 12 Months Ended
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets Goodwill and Intangible Assets
A reconciliation of the change in goodwill and intangible assets for the year ended December 31, 2021 is as follows (in thousands):

 In-Process Research and DevelopmentGoodwill
December 31, 2020$5,700 $1,914 
Impairment charge(5,700)— 
December 31, 2021$— $1,914 

In the fourth quarter of 2021, the Company recognized an impairment charge in connection with our determination that consummating an out-licensing transaction of NPS for further development in breast cancer was unlikely and taking into account the deferred development timelines and a lower probability of success associated with earlier stages of clinical development for the potential development of NPS in other oncology indications. The Company determined that the carrying amount of the IPR&D associated with NPS exceeded the fair value and recorded a $5.7 million impairment charge during the year ended December 31, 2021 and reduced the fair value of the related IPR&D intangible asset to zero. See Note 2 for discussion on how the Company determined the fair value of its IPR&D. There was no impairment charge during the year ended December 31, 2020.

As of December 31, 2021 and 2020, there were no accumulated impairment losses related to goodwill.